ACE inhibitor reduces cardiovascular events by 22BMJ 1999; 319 doi: https://doi.org/10.1136/bmj.319.7211.661 (Published 11 September 1999) Cite this as: BMJ 1999;319:661
- Susan Mayor
Adding an angiotensin converting enzyme (ACE) inhibitor to standard care in patients at high risk of cardiovascular events reduces the risk of cardiovascular death, non-fatal myocardial infarction, and stroke by nearly one quarter. This is the finding of a major study presented at last week's annual meeting of the European Society of Cardiology, held in Barcelona.
In contrast, negative results in a trial with an oral platelet glycoprotein IIb-IIIa antagonist (showing no difference in survival in patients with unstable angina or myocardial infarction when compared with aspirin) seemed to signal the end of the line for these agents, after similar findings in two previous trials.
The first study—the heart outcomes prevention evaluation (HOPE)—showed that patients randomised to the ACE …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial